Based on our study, we propose two optimized low-dose drug combinations of 3 and 4 drugs, referred to as AUT and AUTTala, respectively, for the treatment of ERα + /HER2-/PI3Kα-mutant breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.